Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib in advanced solid tumors
NCT04683354Phase 1Completed
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tunlametinib in solid tumor, sponsored by Shanghai KeChow Pharmaceuticals. Primary endpoints: Number of treatment emergent adverse events, abnormal clinical laboratory and electrocardiograms findings at 7 months, Maximum plasma concentration at 1 month and 2 more. Started Dec 2020; status: completed.
02
Drugs
tunlametinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04683354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683354.